Skip to main content

Leveraging the Intramural Research Program to Effect Foundational Progress in Neurodegenerative Disease

Wednesday, March 30, 2022 - 3:00pm to 4:00pm


Andrew Singleton, Ph.D.
NIH Distinguished Investigator
National Institutes of Health, National Institute on Aging


Dr. Andrew Singleton has published more than 600 articles on a wide variety of topics. He leads a laboratory of about 50 staff, including five principal investigators and three group leaders. Singleton’s lab works on the genetic basis of neurological disorders including Parkinson's disease, Alzheimer’s disease, dystonia, ataxia, dementia with Lewy bodies, and amyotrophic lateral sclerosis (ALS). His team seeks to identify genetic variability that causes or contributes to disease and to use this knowledge to understand the underlying molecular processes. Most recently his work has expanded to the use of multimodal data in predicting disease. Dr. Singleton’s group discovered a number of genetic mutations that cause disease, including the alpha-synuclein multiplication mutation and mutations in LRRK2. Dr. Singleton was a founding member of the International Parkinson Disease Genomics Consortium, which has identified the majority of the known genetic risk factors for Parkinson disease.

The page was last updated on Friday, October 15, 2021 - 10:27am